Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
NOVATO, Calif., June 07, 2017 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017 at 3:20 pm PT in Rancho Palos Verdes, CA.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 415-483-8257
